FR2704393A1 - Nutritional supplement which can be taken orally to optimise growth and maintain robustness of bones - Google Patents
Nutritional supplement which can be taken orally to optimise growth and maintain robustness of bones Download PDFInfo
- Publication number
- FR2704393A1 FR2704393A1 FR9305414A FR9305414A FR2704393A1 FR 2704393 A1 FR2704393 A1 FR 2704393A1 FR 9305414 A FR9305414 A FR 9305414A FR 9305414 A FR9305414 A FR 9305414A FR 2704393 A1 FR2704393 A1 FR 2704393A1
- Authority
- FR
- France
- Prior art keywords
- nutritional supplement
- calcium
- vitamins
- magnesium
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 20
- 210000000988 bone and bone Anatomy 0.000 title claims description 10
- 230000012010 growth Effects 0.000 title claims description 4
- 239000011575 calcium Substances 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- 229930003231 vitamin Natural products 0.000 claims abstract description 7
- 235000013343 vitamin Nutrition 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 7
- 229940088594 vitamin Drugs 0.000 claims abstract description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 7
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 7
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 7
- 239000011712 vitamin K Substances 0.000 claims abstract description 7
- 239000011777 magnesium Substances 0.000 claims abstract description 6
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000011701 zinc Substances 0.000 claims abstract description 6
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000008468 bone growth Effects 0.000 claims abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- 239000010703 silicon Substances 0.000 claims abstract description 4
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002366 mineral element Substances 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims description 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 240000004658 Medicago sativa Species 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000008119 colloidal silica Substances 0.000 claims description 3
- 239000011742 magnesium glycerophosphate Substances 0.000 claims description 3
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000005115 demineralization Methods 0.000 description 5
- 230000002328 demineralizing effect Effects 0.000 description 5
- 206010017076 Fracture Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 239000003698 antivitamin K Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000036004 Cow milk intolerance Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
COMPLEMENT NUTRITIONNEL ABSORBABLE POUR OPTIMISER LA
CROISSANCE ET MAINTENIR LA SOLIDITE DES OS.ABSORBABLE NUTRITIONAL SUPPLEMENT TO OPTIMIZE
GROWTH AND MAINTAIN BONE STRENGTH.
L'invention concerne un complément nutritionnel absorbable destiné à optimiser la croissance osseuse et à maintenir la solidité des os. The invention relates to an absorbable nutritional supplement for optimizing bone growth and maintaining bone strength.
Dans une forme de réalisation pratique, ce complément nutritionnel est utilisé pour compenser les carences alimentaires et ralentir les pertes de tissu osseux liées à l'âge. In a practical embodiment, this nutritional supplement is used to compensate for nutritional deficiencies and to slow down the age-related losses of bone tissue.
Comme on le sait, un "complément nutritionnel" désigne une supplémentation en micronutriments, qui complétant l'alimentation quotidienne, permet à la fois d'agir sur un symptôme et en même temps de renforcer l'organisme dans son ensemble. As we know, a "nutritional supplement" denotes a micronutrient supplementation, which supplements the daily diet, allows both to act on a symptom and at the same time to strengthen the organism as a whole.
La solidité des os dépend d'un remodelage constant d'une armature de collagène sur laquelle sont cristallisés des minéraux, en particulier du calcium. Pour que le phénomène complexe de remodelage conduise à un os dense, résistant aux risques de fractures et de tassement, d'autres éléments sont nécessaires. La vitamine K est nécessaire pour la fixation de ce calcium. Le magnésium, le zinc, la silice, les vitamines C et B6 sont essentielles pour le bon fonctionnement des cellules qui fabriquent l'armature de collagène sur laquelle le calcium va se déposer. The strength of the bones depends on a constant remodeling of a collagen framework on which minerals, in particular calcium, are crystallized. For the complex phenomenon of remodeling to lead to dense bone, resistant to the risks of fractures and compaction, other elements are necessary. Vitamin K is necessary for the fixation of this calcium. Magnesium, zinc, silica, vitamins C and B6 are essential for the proper functioning of the cells that manufacture the framework of collagen on which the calcium will deposit.
On sait que le début de la perte osseuse se situe vers l'âge de 35 ans. We know that the onset of bone loss is around the age of 35.
A partir de cet âge, la plupart des individus, notamment les femmes, ont en moyenne besoin d'un supplément quotidien de l'ordre de 500 mg de calcium pour freiner la déminéralisation associée à l'âge. From this age, most individuals, especially women, need an average daily supplement of around 500 mg of calcium to slow down the demineralization associated with age.
Il existe de nombreux facteurs qui augmentent le risque de déminéralisation. On peut citer la maigreur, une peau claire, l'absence d'exposition au soleil, des apports excessifs en phosphore qui sont notamment présents dans les boissons sucrées recherchées par les enfants, un excès de café et d'alcool ou de tabac, la sédentarité, une période d'immobilisation prolongée, des efforts sportifs intensifs, le surmenage ou le stress menant à des troubles du cycle menstruel, ainsi que certains traitements prolongés, tels que corticoïdes, anti-vitamines K, pansements gastriques contenant des sels d'aluminium. There are many factors that increase the risk of demineralization. We can cite thinness, clear skin, absence of exposure to the sun, excessive phosphorus intakes which are particularly present in sugary drinks sought by children, an excess of coffee and alcohol or tobacco, a sedentary lifestyle, a prolonged period of immobilization, intensive sports efforts, overwork or stress leading to disorders of the menstrual cycle, as well as certain prolonged treatments, such as corticoids, anti-vitamins K, gastric dressings containing aluminum salts .
Une supplémentation calcique est donc nécessaire dans toutes les circonstances, aussi bien chez l'enfant ou l'adolescent dont la croissance est rapide, que chez les personnes âgées pour qui l'absorption du calcium est moins efficace. On sait qu'un apport calcique alimentaire diminue les risques de fracture du col du fémur. Mais on sait également qu'une simple supplémentation en calcium n'est pas suffisante. Calcium supplementation is therefore necessary in all circumstances, both in children or adolescents who are growing rapidly, and in the elderly for whom calcium absorption is less effective. We know that a dietary calcium intake reduces the risk of fracture of the femoral neck. But we also know that a simple calcium supplementation is not enough.
Pour pallier ces inconvénients, on fait le plus fréquemment appel à des traitements médicamenteux lourds et qui entraînent souvent des effets secondaires. To overcome these drawbacks, heavy drug treatments are used most frequently and which often have side effects.
Par ailleurs, les individus, notamment les jeunes adultes, se soucient assez peu de ces problèmes, dont les conséquences sont révélées sur le tard. In addition, individuals, especially young adults, care very little about these problems, the consequences of which are revealed late.
L'invention vise à pallier ces inconvénients. Elle concerne un complément nutritionnel destiné à optimiser la croissance des os, à maintenir leur solidité et, s'il y a lieu, à les consolider. The invention aims to overcome these drawbacks. It concerns a nutritional supplement intended to optimize the growth of bones, to maintain their solidity and, if necessary, to consolidate them.
Ce complément nutritionnel se caractérise en ce qu'il contient:
- du calcium, du magnésium, du zinc et du silicium;
- une association de vitamines K, C et B6;
- des excipients.This nutritional supplement is characterized in that it contains:
- calcium, magnesium, zinc and silicon;
- a combination of vitamins K, C and B6;
- excipients.
En d'autres termes, l'invention consiste à réaliser un complément nutritionnel formé par la sélection de certains sels minéraux et de certaines vitamines, qui en proportions optimales, conduisent à des effets nettement améliorés. Ainsi, la synergie entre ces micronutriments (éléments minéraux et vitamines) permet la croissance optimale de l'os, le maintien de sa solidité et une qualité de réparation satisfaisante en cas de fracture. Si un seul de ces éléments est absent, c'est toute la chaîne des opérations nécessaires à Ia bonne santé de l'os qui en est affectée. In other words, the invention consists in making a nutritional supplement formed by the selection of certain mineral salts and certain vitamins, which in optimal proportions, lead to markedly improved effects. Thus, the synergy between these micronutrients (mineral elements and vitamins) allows optimal bone growth, maintaining its solidity and a satisfactory quality of repair in the event of a fracture. If only one of these elements is absent, the entire chain of operations necessary for the good health of the bone is affected.
Avantageusement, en pratique:
- le calcium est apporté sous forme de poudre de coquille d'huître et de citrate de calcium;
- le magnésium est apporté sous forme de glycérophosphate facile à assimiler, voire sous forme d'acétate;
- le zinc est apporté sous forme de citrate, également facile à assimiler
- le silicium qui stimule la constitution de l'armature de collagène et accélère la minéralisation de l'os, est apporté sous forme de silice colloïdale;
- la vitamine K, qui est indispensable à la formation du site de calcification et qui accessoirement réduit la fuite urinaire de calcium chez les ostéoporotiques, est apportée sous la forme naturelle d'Alfalfa (luzerne), notamment sous forme de poudre dont on sait qu'elle est également riche en calcium et en vitamine C;;
- la vitamine C, nécessaire à la synthèse du collagène et la vitamine
B6 nécessaire pour assurer la solidité de l'armature de collagène, sont apportées sous forme naturelle;
- comme excipients, on utilise de la cellulose et du stéarate de magnésium.Advantageously, in practice:
- calcium is provided in the form of oyster shell powder and calcium citrate;
- Magnesium is provided in the form of glycerophosphate which is easy to assimilate, or even in the form of acetate;
- zinc is supplied in the form of citrate, also easy to assimilate
- the silicon which stimulates the constitution of the collagen framework and accelerates the mineralization of the bone, is provided in the form of colloidal silica;
- Vitamin K, which is essential for the formation of the calcification site and which incidentally reduces the urinary leakage of calcium in osteoporotics, is provided in the natural form of Alfalfa (alfalfa), in particular in the form of powder which is known to be 'is also rich in calcium and vitamin C;
- vitamin C, necessary for the synthesis of collagen and vitamin
B6 necessary to ensure the solidity of the collagen reinforcement, are brought in natural form;
- as excipients, cellulose and magnesium stearate are used.
Dans une forme d'exécution avantageuse, le complément nutritionnel selon l'invention comprend en pour cent en poids
- poudre de coquille d'huître 20,91 %
- citrate de calcium 23,64 %
- glycérophosphate de magnésium 37,27 %
- citrate de zinc 1,82 %
- poudre d'Alfalfa contenant
de la vitamine K 1,82 %
- vitamine C 1,82 %
- vitamine B6 0,09 %
- silice colloïdale 0,27 %
- excipient 12,36 %
par exemple:
cellulose 11,36 %
stéarate de magnésium I %
Pour garantir l'intégrité des différents composés, on effectue avantageusement Ia formulation de la manière suivante. Dans un premier temps, on granule en phase humide les excipients et les principaux composés.Puis, dans un deuxième temps, on mélange en phase sèche les vitamines et les principes actifs fragiles
Le complément nutritionnel conforme à l'invention, se présente sous forme sèche, notamment sous forme de granules, de gélules, de poudre, et avantageusement de comprimés. Ce complément peut être facilement absorbé, aussi bien par des enfants, des adolescents, des adultes que des vieillards.In an advantageous embodiment, the nutritional supplement according to the invention comprises in percent by weight
- oyster shell powder 20.91%
- calcium citrate 23.64%
- magnesium glycerophosphate 37.27%
- zinc citrate 1.82%
- Alfalfa powder containing
vitamin K 1.82%
- vitamin C 1.82%
- vitamin B6 0.09%
- 0.27% colloidal silica
- excipient 12.36%
for example:
cellulose 11.36%
magnesium stearate I%
To guarantee the integrity of the various compounds, the formulation is advantageously carried out in the following manner. First, the excipients and the main compounds are granulated in the wet phase. Then, in the dry phase, the fragile vitamins and active ingredients are mixed.
The nutritional supplement according to the invention is in dry form, in particular in the form of granules, capsules, powder, and advantageously tablets. This supplement can be easily absorbed by children, adolescents, adults and the elderly.
On utilise de préférence la formule comprimés. Par exemple, avec des comprimés de 550 mg (voir formule détaillée ci-dessus), on a obtenu sur des adultes de bons résultats avec des prises avalées de deux comprimés pendant les repas le matin et le soir pendant deux à trois mois. De même, on a obtenu de bons résultats avec des prises analogues en permanence pendant la grossesse ou pendant la ménopause. The tablet formula is preferably used. For example, with 550 mg tablets (see detailed formula above), good results have been obtained on adults by taking two tablets swallowed during meals in the morning and in the evening for two to three months. Likewise, good results have been obtained with similar intakes continuously during pregnancy or during menopause.
Ce complément nutritionnel minéral osseux synergique permet:
- d'optimiser la croissance osseuse,
- de diminuer les risques de déminéralisation pendant la grossesse et
la lactation;
- de contribuer à ralentir les phénomènes de déminéralisation liés à
la ménopause et à l'âge;
- de favoriser la solidité des os des personnes âgées;
- de faciliter Ia consolidation des fractures;
- de compenser des régimes déficients en calcium, notamment en
cas d'intolérance aux produits laitiers ou en cas de régimes
hypocaloriques;
- de compenser la déminéralisation due à certains traitements au
long cours, tels que cortoldes, anti-vitamines K, pansements
gastriques contenant des sels d'aluminium. This synergistic bone mineral nutritional supplement allows:
- optimize bone growth,
- reduce the risk of demineralization during pregnancy and
lactation;
- to help slow down the demineralization phenomena linked to
menopause and age;
- to promote the solidity of the bones of the elderly;
- to facilitate the consolidation of fractures;
- compensate for calcium deficient diets, especially
dairy intolerance or dieting
low calorie;
- to compensate for the demineralization due to certain treatments
long courses, such as cortoldes, anti-vitamin K, dressings
gastric containing aluminum salts.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305414A FR2704393B1 (en) | 1993-04-30 | 1993-04-30 | Absorbable nutritional supplement to optimize growth and maintain strong bones. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305414A FR2704393B1 (en) | 1993-04-30 | 1993-04-30 | Absorbable nutritional supplement to optimize growth and maintain strong bones. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2704393A1 true FR2704393A1 (en) | 1994-11-04 |
| FR2704393B1 FR2704393B1 (en) | 1995-06-02 |
Family
ID=9446827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9305414A Expired - Fee Related FR2704393B1 (en) | 1993-04-30 | 1993-04-30 | Absorbable nutritional supplement to optimize growth and maintain strong bones. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2704393B1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2723682A1 (en) * | 1994-08-19 | 1996-02-23 | Boiron | Absorbable nutritional supplement for children and adolescents, to ensure daily micronutrient intake |
| DE4446024A1 (en) * | 1994-12-22 | 1996-06-27 | Martin Dr Kohlmeier | Use of a vitamin from the K group |
| DE19503190A1 (en) * | 1995-02-01 | 1996-08-08 | Dietl Hans | Means for influencing disorders of bone formation |
| FR2737849A1 (en) * | 1995-08-18 | 1997-02-21 | Boiron | Orally administered food supplement for adults of over forty |
| FR2785503A1 (en) * | 1998-11-06 | 2000-05-12 | Pharma Futura | Aragonite orthorhombic calcium carbonate from mother of pearl is used to make foods for the prevention and treatment of osteoporosis |
| WO2001084963A1 (en) * | 2000-05-11 | 2001-11-15 | Pharma Futura | Edible composition containing micronised nacre powder |
| GB2370503A (en) * | 2000-12-27 | 2002-07-03 | Novartis Nutrition Ag | Compositions comprising vitamin K |
| US6503529B1 (en) * | 1999-12-22 | 2003-01-07 | Goen Group, Inc. | Blood type methods and dietary supplements |
| EP1340428A2 (en) * | 1997-11-24 | 2003-09-03 | Bristol-Myers Squibb Company | Fortified confectionery and methods of preparation thereof |
| EP1949801A1 (en) * | 2006-11-17 | 2008-07-30 | Maria Ascension Fernandez Jimenez | Nutritious and regenerative drink |
| WO2009115827A1 (en) * | 2008-03-20 | 2009-09-24 | The Nottingham Trent University | Food supplement |
| US7655264B2 (en) | 1997-08-29 | 2010-02-02 | Mcneil-Ppc, Inc. | Process for promoting calcium absorption |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0330648A (en) * | 1989-06-28 | 1991-02-08 | Ajinomoto Co Inc | Readily absorbable mineral-containing food and drink |
| EP0497287A1 (en) * | 1991-01-28 | 1992-08-05 | Finfonta Import Ky | Food supplement for strengthening bone and joints |
| WO1992012714A2 (en) * | 1991-01-23 | 1992-08-06 | Food supplement | |
| WO1992021355A1 (en) * | 1991-05-28 | 1992-12-10 | The Procter & Gamble Company | Calcium, trace mineral, vitamin d and drug therapy combinations |
-
1993
- 1993-04-30 FR FR9305414A patent/FR2704393B1/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0330648A (en) * | 1989-06-28 | 1991-02-08 | Ajinomoto Co Inc | Readily absorbable mineral-containing food and drink |
| WO1992012714A2 (en) * | 1991-01-23 | 1992-08-06 | Food supplement | |
| EP0497287A1 (en) * | 1991-01-28 | 1992-08-05 | Finfonta Import Ky | Food supplement for strengthening bone and joints |
| WO1992021355A1 (en) * | 1991-05-28 | 1992-12-10 | The Procter & Gamble Company | Calcium, trace mineral, vitamin d and drug therapy combinations |
Non-Patent Citations (1)
| Title |
|---|
| PATENT ABSTRACTS OF JAPAN vol. 15, no. 150 (C - 0824) 16 April 1991 (1991-04-16) * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2723682A1 (en) * | 1994-08-19 | 1996-02-23 | Boiron | Absorbable nutritional supplement for children and adolescents, to ensure daily micronutrient intake |
| DE4446024A1 (en) * | 1994-12-22 | 1996-06-27 | Martin Dr Kohlmeier | Use of a vitamin from the K group |
| DE19503190A1 (en) * | 1995-02-01 | 1996-08-08 | Dietl Hans | Means for influencing disorders of bone formation |
| US5985335A (en) * | 1995-02-01 | 1999-11-16 | Orthomol Pharmazeutische Vertriebs Gmbh | Agent for acting upon bone formation disturbances containing alkaline citrates, lactates and/or malates |
| FR2737849A1 (en) * | 1995-08-18 | 1997-02-21 | Boiron | Orally administered food supplement for adults of over forty |
| US7655264B2 (en) | 1997-08-29 | 2010-02-02 | Mcneil-Ppc, Inc. | Process for promoting calcium absorption |
| EP1340428A2 (en) * | 1997-11-24 | 2003-09-03 | Bristol-Myers Squibb Company | Fortified confectionery and methods of preparation thereof |
| EP1340428A3 (en) * | 1997-11-24 | 2005-03-02 | Bristol-Myers Squibb Company | Fortified confectionery and methods of preparation thereof |
| FR2785503A1 (en) * | 1998-11-06 | 2000-05-12 | Pharma Futura | Aragonite orthorhombic calcium carbonate from mother of pearl is used to make foods for the prevention and treatment of osteoporosis |
| US6503529B1 (en) * | 1999-12-22 | 2003-01-07 | Goen Group, Inc. | Blood type methods and dietary supplements |
| WO2001084963A1 (en) * | 2000-05-11 | 2001-11-15 | Pharma Futura | Edible composition containing micronised nacre powder |
| FR2808657A1 (en) * | 2000-05-11 | 2001-11-16 | Pharma Futura | Edible composition containing micronized nacre powder of specific particle size, as high bioavailability calcium supplement for promoting osteogenesis in humans or animals |
| GB2370503A (en) * | 2000-12-27 | 2002-07-03 | Novartis Nutrition Ag | Compositions comprising vitamin K |
| EP1949801A1 (en) * | 2006-11-17 | 2008-07-30 | Maria Ascension Fernandez Jimenez | Nutritious and regenerative drink |
| WO2009115827A1 (en) * | 2008-03-20 | 2009-09-24 | The Nottingham Trent University | Food supplement |
| US9375029B2 (en) | 2008-03-20 | 2016-06-28 | The Nottingham Trent University | Food supplement |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2704393B1 (en) | 1995-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030190369A1 (en) | Vitamin formulation for enhancing bone strength | |
| CN1956734A (en) | Multi-vitamin and mineral nutritional supplements | |
| FR2704393A1 (en) | Nutritional supplement which can be taken orally to optimise growth and maintain robustness of bones | |
| EP0859619A1 (en) | Multiple vitamin supplement composition | |
| KR20070054739A (en) | Total enteral nutritious composition | |
| US5925335A (en) | Dental formulation | |
| Faine | Dietary factors related to preservation of oral and skeletal bone mass in women | |
| US6265391B1 (en) | Method for preventing peripheral nerve damage | |
| JP3862600B2 (en) | Eggshell membrane-containing tablets | |
| FR2620907A1 (en) | MAGNESIUM ADDITIVE FOR NUTRIENT, FOOD AND DRUG SUBSTANCES | |
| FR2737849A1 (en) | Orally administered food supplement for adults of over forty | |
| CN104799277A (en) | Chewable colla corii asini tablet and preparation method thereof | |
| Dowd | Role of calcium, vitamin D, and other essential nutrients in the prevention and treatment of osteoporosis | |
| FR2704392A1 (en) | Nutritional supplement which can be taken orally to improve and optimise individuals' levels of physical and mental activity | |
| FR2704391A1 (en) | Nutritional supplement which can be taken orally to facilitate adaptation to daily stress | |
| Whiting et al. | Calcium supplementation | |
| JP7505831B2 (en) | Hypertension improving agent containing seaweed extract, and functional foods, quasi-drugs and medicines containing said hypertension improving agent | |
| CN110074306A (en) | A kind of inulin solid beverage and preparation method thereof | |
| FR2723680A1 (en) | Absorbable nutritional supplement to ensure daily micronutrient intake | |
| CN110089754A (en) | Liver and gallbladder health care product | |
| KR20190012943A (en) | Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention | |
| JP4435882B2 (en) | Alcohol absorption inhibiting composition | |
| CA2385774A1 (en) | Composition to reduce food cravings and supress the appetite | |
| FR2723682A1 (en) | Absorbable nutritional supplement for children and adolescents, to ensure daily micronutrient intake | |
| Biggs et al. | Beyond the sugar: Chemicals in sodas and their link to systemic diseases and oral health April 21, 2017 Dental hygiene students study the research on ingredients in sodas and examine systemic links to oral health. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |